Lexaria Bioscience Warrant
LEXXW
LEXXW was delisted on the 13th of January, 2026.
0 hedge funds and large institutions have $0 invested in Lexaria Bioscience Warrant in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 3 closing their positions.
12.06% less ownership
Funds ownership: 12.06% → 0% (-12%)
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $97 → $0 (-$97)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$96 |
| 2 |
CS
Clear Street
New York
|
-$1 |
LEXXW Hedge Fund Activity: Q1 2026 in Review
0 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q1 2026, worth a combined $0 — down 100% from $97 a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LEXXW and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Two Sigma Securities, exiting entirely with an estimated $96 sold.
- 0 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q1 2026, down from 3 in Q4 2025.
- Funds reported $0 of Lexaria Bioscience Warrant stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Lexaria Bioscience Warrant positions in Q1 2026 and 3 closed out, a net change of -3 holders.
- The largest Lexaria Bioscience Warrant seller in Q1 2026 was Two Sigma Securities, an estimated $96 sold.
Based on aggregated 13F filings for Q1 2026.